10-K: NovelStem International Corp. Reports $4.2 Million Net Loss in 2023 Amidst Biotech Development Challenges

NovelStem International Corp. reported a net loss of $4.2 million for 2023, primarily due to losses from its investment in NewStem and litigation expenses.

Summary

• NovelStem International Corp., a development-stage biotechnology holding company, reported a net loss of approximately $4.2 million for the year ended December 31, 2023, compared to a net loss of $766,000 in 2022.
• The company's primary assets are its equity interests in NewStem Ltd., an Israeli biotech company, and NetCo Partners, a legacy joint venture.
• NovelStem's operating expenses increased significantly due to litigation costs related to a dispute with its NetCo joint venture partner, totaling approximately $2.9 million in 2023.
• The company's general and administrative expenses decreased to $665,000 in 2023 from $744,000 in 2022, primarily due to lower professional fees and insurance costs.
• NovelStem depends entirely on earnings and cash flow from its investments in NewStem and NetCo, and it has not received any dividend payments from NewStem in 2023 or 2022.
• The company received distributions of earnings from NetCo of $6,875 and $12,591 for the fiscal years ended December 31, 2023 and 2022, respectively.
• NewStem, in which NovelStem holds a 30.51% equity interest, is focused on developing stem cell-based technologies for cancer research and has incurred losses since inception.
• NovelStem has identified material weaknesses in its internal control over financial reporting and disclosure controls and procedures.
• As of December 31, 2023, NovelStem had current assets of approximately $87,000 and current liabilities of approximately $346,000.

Sentiment

Score: 3

Explanation: The document reveals significant financial losses, material weaknesses in internal controls, and dependence on a struggling subsidiary, resulting in a negative outlook. While there are some positive aspects, the overall tone is concerning from an investment perspective.

Positives

• General and administrative expenses decreased by approximately $79,000 in 2023 compared to 2022.
• The company received a favorable ruling on two key issues in the NetCo arbitration, confirming its contractual rights.
• NovelStem has secured non-recourse litigation funding to maximize the value of NetCo.

Negatives

• The company experienced a substantial increase in net loss, primarily due to litigation expenses and losses from its investment in NewStem.
• NovelStem has identified material weaknesses in its internal control over financial reporting.
• The company's investments in NewStem and NetCo are illiquid and have limited liquidity rights.
• NewStem has incurred losses since inception and has generated minimal revenues.
• The company depends entirely on earnings and cash flow from NewStem and NetCo.
• The company has a significant accumulated deficit of approximately $293 million.
• The company's ability to continue as a going concern is dependent on additional financing and the profitability of NewStem.

Risks

• The company's primary assets are illiquid ownership interests in NewStem and NetCo.
• NovelStem depends on key personnel, and the loss of their services could harm the company.
• The company and NewStem have limited operating histories and have generated minimal revenue to date.
• Rapid technological change could cause NewStem's products to become obsolete.
• The company's ability to pay dividends is limited by its holding company structure.
• The company's stock is subject to price volatility and low trading volumes.
• The company may be deemed an investment company, which could impose burdensome compliance requirements.
• NewStem's ability to obtain regulatory approvals for its products is uncertain.
• The company's ongoing viability depends on NewStem's ability to successfully develop and commercialize its products.
• Disputes with C.P. Group, the company's partner in NetCo, could affect the value of the investment and distributions.
• NetCo's business is intensely competitive and hit-driven, and it may not deliver successful products.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to continue to incur greater expenses in the near future as it expands its business, including funding NewStem, or enters into strategic partnerships. The company will need to obtain additional funds to continue its operations. Management plans include additional financing and fundraising until its equity investment in NewStem is profitable.

Management Comments

• Jan Loeb, the Executive Chairman, also serves as the Chairman of NewStem's Board of Directors and guides NewStem's financial and strategic planning.
• Mr. Loeb serves as the de facto Chief Financial Officer and Chief Strategic Officer of NewStem.

Industry Context

The biotechnology industry is characterized by rapid technological advancements and intense competition. NovelStem's focus on stem cell-based technologies places it in a high-growth but also high-risk sector. The company's success is heavily dependent on the ability of NewStem to develop and commercialize its products, which is subject to regulatory hurdles and market acceptance.

Comparison to Industry Standards

• NovelStem's financial performance is significantly below industry standards for established biotech companies, which typically have revenue streams from product sales or licensing agreements.
• The company's reliance on equity investments and lack of product revenue is more characteristic of early-stage biotech startups.
• Compared to companies like CRISPR Therapeutics or Editas Medicine, which are also focused on gene editing and stem cell technologies, NovelStem is at a much earlier stage of development and has not yet achieved significant clinical milestones or commercial revenue.
• The company's high operating losses and dependence on external funding are common among development-stage biotech firms, but the magnitude of the losses and the identified material weaknesses in internal control are concerning.
• The litigation expenses related to NetCo are unusual for a biotech company and highlight the risks associated with the company's diversified holdings.

Legal Proceedings

• The company was involved in an arbitration proceeding with its NetCo joint venture partner, C.P. Group, which concluded in July 2023.
• The arbitrator ruled in the company's favor on two key issues but did not award any damages or cede operating control of the joint venture to the company.
• The company has secured non-recourse litigation funding to maximize the value of NetCo.

Related Party Transactions

• The company entered into note agreements with Jan Loeb, its Executive Chairman, and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $650,000 for working capital needs.
• The company entered into a long-term note payable with a shareholder for $300,000 for working capital.
• The company reimbursed NewStem for audit and audit-related costs of approximately $58,000 and $105,000 during the years ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss and the identified material weaknesses in internal control.
• Employees of NewStem were impacted by the cost reduction plan and the dismissal of most employees in December 2023.
• The company's ability to continue as a going concern is dependent on additional financing and the profitability of NewStem, which could impact all stakeholders.
• The company's ability to maximize the value of NetCo is impacted by the ongoing dispute with its joint venture partner.

Next Steps

• The company intends to focus on strengthening its internal controls.
• Management expects to make progress towards reducing the risk that the material weakness could result in a material misstatement of the company's annual or interim financial statements.
• The company is in negotiations to acquire the remainder of NewStem in exchange for shares of Company stock.
• The company will need to obtain additional funds to continue its operations.

Key Dates

Keywords

biotechnology, stem cells, oncology, diagnostics, therapeutics, NewStem, NetCo, litigation, financial results, internal control, equity investment, hPSCs, HhPSCs